Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Braidwell LP

Braidwell LP boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 148.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,284,472 shares of the company’s stock after buying an additional 767,242 shares during the quarter. Braidwell LP’s holdings in Arvinas were worth $31,637,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in Arvinas by 137.2% during the second quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock worth $2,292,000 after acquiring an additional 49,799 shares during the last quarter. Candriam S.C.A. boosted its position in shares of Arvinas by 32.0% during the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after buying an additional 147,904 shares during the period. Magnetar Financial LLC boosted its position in shares of Arvinas by 112.7% during the second quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after buying an additional 22,245 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Arvinas by 32.6% during the second quarter. Bank of New York Mellon Corp now owns 235,096 shares of the company’s stock worth $6,258,000 after buying an additional 57,835 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Arvinas during the third quarter worth $3,442,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $25.98 on Friday. The business’s 50 day simple moving average is $25.66 and its 200-day simple moving average is $26.81. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -5.56 and a beta of 1.96. Arvinas, Inc. has a 12 month low of $21.17 and a 12 month high of $53.08.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analysts’ expectations of $60.56 million. Arvinas’s revenue was up 196.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.18) EPS. On average, equities analysts anticipate that Arvinas, Inc. will post -3.32 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. Stephens began coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price for the company. Oppenheimer decreased their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. BMO Capital Markets decreased their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Arvinas in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.08.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.